American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Marańda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory Richter's transformation and de novo diffuse large B-cell lymphoma
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Foss, F. M.; Isufi, I.; Kothari, S. K.; Ding, W.; Brander, D. M.; Sitlinger, A.; Rosenthal, A. C.; Leis, J. F.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Cardiovascular and metabolic risk in patients with chronic myeloid leukemia in chronic phase receiving first-line BCR-ABL1 tyrosine kinase inhibitors in the United States: Baseline and six-month follow-up results from a prospective real-world observational study
    Meeting Abstract

    Mauro, M. J.; Oehler, V. G.; Thompson, J. E.; McCloskey, J. K.; Heinrich, M. C.; Dakhil, S. R.; DeGutis, I.; Tabano, D.; Khan, W.; Moslehi, J. J.
    Blood (2020)

    Fulltext@MSK | Save
  • Economic and clinical burden of virus-associated hemorrhagic cystitis in patients following allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    McGuirk, J. P.; Divine, C.; Moon, S. H.; Chandak, A.; Zhang, Z. J.; Papanicolaou, G. A.
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics-subgroup analysis
    Meeting Abstract

    Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation
    Meeting Abstract

    Mato, A.; Tang, B.; Azmi, S.; Yang, K. R.; Stern, J. C.; Hedrick, E.; Huang, J.; Sharman, J. P.
    Blood (2020)

    Fulltext@MSK | Save
  • Real-world prognostic biomarker testing, treatment patterns and dosing among 1461 Patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the informCLL prospective observational registry
    Meeting Abstract

    Mato, A. R.; Barrientos, J. C.; Sharman, J. P.; Brander, D. M.; Gutierrez, M.; Kadish, K.; Arango-Hisijara, I.; Upasani, S.; Han, J.; Huang, Q.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Rationale for and results of a phase I study of the TGF-beta 1/3 inhibitor AVID200 in subjects with myelofibrosis: MPN-RC 118 trial
    Meeting Abstract

    Mascarenhas, J.; Kosiorek, H. E.; Varricchio, L.; Bhave, R.; Kuykendall, A. T.; Komrokji, R.; Gerds, A. T.; Palmer, J. M.; Gabler, A. R.; Sandy, L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma: Promising safety and encouraging efficacy in dose escalation cohorts
    Meeting Abstract

    Matasar, M. J.; Cheah, C. Y.; Yoon, D. H.; Assouline, S. E.; Bartlett, N. L.; Ku, M.; Giri, P.; Johnston, A.; Flinn, I. W.; Goy, A. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Universal: An allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Matous, J. V.; Liedtke, M.; Sidana, S.; Malik, S.; Nath, R.; Oluwole, O. O.; Karski, E. E.; Lovelace, W.; Zhou, X.; more...
    Blood (2020)

    Fulltext@MSK | Save